新型冠状病毒感染相关心肌损伤研究现状

doi:10.19983/j.issn.2096-8493.20230101

摘要/Abstract

摘要：

2019年年末,由严重急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)引起的新型冠状病毒感染(coronavirus disease 2019,COVID-19)迅速扩散,在全球范围内出现大流行,由于其毒株变异速度快、传染性强,给世界各国带来了沉重的医疗负担和经济负担。COVID-19可累及全身多个系统,除了典型的呼吸系统症状外,COVID-19患者还可并发心肌损伤。随着研究的不断深入,目前对COVID-19相关心肌损伤的认知也得到进一步提升。笔者对COVID-19相关心肌损伤的研究现状作一综述,以加深临床医生对该疾病的认识。

关键词: 冠状病毒感染, 心肌疾病, 总结性报告(主题)

Abstract:

At the end of 2019, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly and became pandemic worldwide. Due to rapid mutation and strong infectivity of the virus strains, COVID-19 has brought heavy medical and economic burden to countries around the world. COVID-19 may infected multiple systems of the body. In addition to typical respiratory symptoms, patients with COVID-19 may be combined with myocardial injury. With the further studies, there is a better understanding of COVID-19-related myocardial injury currently. The current researches that involved COVID-19-related myocardial injury were summarized to deepen clinicians’ understanding.

Key words: Coronavirus infections, Cardiomyopathies, Consensus development conferences as topic

中图分类号:

林荣梅, 陆霓虹. 新型冠状病毒感染相关心肌损伤研究现状[J]. 结核与肺部疾病杂志, 2023, 4(6): 493-498. doi: 10.19983/j.issn.2096-8493.20230101

Lin Rongmei, Lu Nihong. Current status of myocardial injury associated with the coronavirus disease 2019[J]. Journal of Tuberculosis and Lung Disease, 2023, 4(6): 493-498. doi: 10.19983/j.issn.2096-8493.20230101

图/表 1

参考文献 37

[1]	中国医师协会心血管内科医师分会. 新型冠状病毒感染与心血管疾病诊疗中国专家共识(2023). 中华心血管病杂志(网络版), 2023, 6(1):1-22. doi:10.3760/cma.j.cn116031.2023.1000136.
[2]	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5. pmid: 31986264
[3]	Gluckman TJ, Bhave NM, Allen LA, et al. 2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol, 2022, 79(17):1717-1756. doi:10.1016/j.jacc.2022.02.003. pmid: 35307156
[4]	国家老年医学中心, 中国老年医学学会心电与心功能分会, 北京医学会心血管病学分会影像学组, 等. 新型冠状病毒感染相关心肌损伤、心肌炎和感染后状态管理专家共识(第二版). 中国循环杂志, 2023, 38(2):105-115. doi:10.3969/j.issn.1000-3614.2023.02.001.
[5]	Bavishi C, Bonow RO, Trivedi V, et al. Special Article-Acute myocardial injury in patients hospitalized with COVID-19 infection: A review. Prog Cardiovasc Dis, 2020, 63(5):682-689. doi:10.1016/j.pcad.2020.05.013. pmid: 32512122
[6]	尹亮, 刘德敏, 谷国强. 新型冠状病毒肺炎相关心肌损伤机制及治疗进展. 国际心血管病杂志, 2021, 48(6):321-325. doi:10.3969/j.issn.1673-6583.2021.06.001.
[7]	B K A, Chaudhuri D. A Review of Acute Myocardial Injury in Coronavirus Disease 2019. Cureus, 2020, 12(6):e8426. doi:10.7759/cureus.8426.
[8]	新型冠状病毒感染心肌损伤无创影像学评估中国专家共识专家委员会. 新型冠状病毒感染心肌损伤无创影像学评估中国专家共识. 中国循环杂志, 2023, 38(5):496-507. doi:10.3969/j.issn.1000-3614.2023.05.003.
[9]	Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol, 2020, 109(5):531-538. doi:10.1007/s00392-020-01626-9. pmid: 32161990
[10]	Timpau AS, Miftode RS, Leca D, et al. A Real Pandora’s Box in Pandemic Times: A Narrative Review on the Acute Cardiac Injury Due to COVID-19. Life (Basel), 2022, 12(7):1085. doi:10.3390/life12071085.
[11]	Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med, 2020, 173(4):268-277. doi:10.7326/M20-2003. pmid: 32374815
[12]	Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol, 2020, 5(11):1265-1273. doi:10.1001/jamacardio.2020.3557.
[13]	Abate SM, Mantefardo B, Nega S, et al. Global burden of acute myocardial injury associated with COVID-19: A systematic review, meta-analysis, and meta-regression. Ann Med Surg (Lond), 2021, 68:102594. doi:10.1016/j.amsu.2021.102594.
[14]	Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med, 2020, 46(5):846-848. doi:10.1007/s00134-020-05991-x. pmid: 32125452
[15]	Li L, Hill J, Spratt JC, et al. Myocardial injury in severe COVID-19: Identification and management. Resuscitation, 2021, 160:16-17. doi:10.1016/j.resuscitation.2020.11.040. pmid: 33450334
[16]	Zheng YY, Ma YT, Zhang JY, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol, 2020, 17(5):259-260. doi:10.1038/s41569-020-0360-5.
[17]	Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020, 395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3. pmid: 32171076
[18]	Yao XH, Luo T, Shi Y, et al. A cohort autopsy study defines COVID-19 systemic pathogenesis. Cell Res, 2021, 31(8):836-846. doi:10.1038/s41422-021-00523-8.
[19]	Li X, Guan B, Su T, et al. Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis. Heart, 2020, 106(15):1142-1147. doi:10.1136/heartjnl-2020-317062. pmid: 32461330
[20]	Skendros P, Mitsios A, Chrysanthopoulou A, et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest, 2020, 130(11):6151-6157. doi:10.1172/JCI141374.
[21]	Fox SE, Falgout L, Vander Heide RS. COVID-19 myocarditis: quantitative analysis of the inflammatory infiltrate and a proposed mechanism. Cardiovasc Pathol, 2021, 54:107361. doi:10.1016/j.carpath.2021.107361.
[22]	Bajaj R, Sinclair HC, Patel K. et al. Delayed-onset myocarditis following COVID-19. Lancet Respir Med, 2021, 9(4): e32-e34. doi:10.1016/S2213-2600(21)00085-0.
[23]	Castiello T, Georgiopoulos G, Finocchiaro G, et al. COVID-19 and myocarditis: a systematic review and overview of current challenges. Heart Fail Rev, 2022, 27(1):251-261. doi:10.1007/s10741-021-10087-9.
[24]	Tajbakhsh A, Gheibi Hayat SM, Taghizadeh H, et al. COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev Anti Infect Ther, 2021, 19(3):345-357. doi:10.1080/14787210.2020.1822737.
[25]	Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol, 2009, 53(17):1475-1487. doi:10.1016/j.jacc.2009.02.007. pmid: 19389557
[26]	国家老年医学中心/国家老年疾病临床医学研究中心, 中国老年医学学会心血管病分会, 北京医学会心血管病学会影像学组. 新型冠状病毒肺炎相关心肌损伤的临床管理专家建议(第一版). 中国循环杂志, 2020, 35(4):326-330. doi:10.3969/j.issn.1000-3614.2020.04.002.
[27]	Angus DC, Derde L, Al-Beidh F, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA, 2020, 324(13):1317-1329. doi:10.1001/jama.2020.17022.
[28]	Ledford H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature, 2020, 582(7813):469. doi:10.1038/d41586-020-01824-5.
[29]	Sheng CC, Sahoo D, Dugar S, et al. Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study). Clin Cardiol, 2020, 43(10):1055-1063. doi:10.1002/clc.23451.
[30]	孙婧, 党亚南, 张霄娜. 芪冬颐心口服液联合环磷腺苷葡胺对病毒性心肌炎患者心肌酶谱、细胞免疫功能及血浆心钠素水平的影响. 现代中西医结合杂志, 2019, 28(26):2925-2928. doi:10.3969/j.issn.1008-8849.2019.26.019.
[31]	黄鹤, 吴钢, 赵庆彦, 等. 新型冠状病毒肺炎合并心律失常的诊疗建议. 中华心律失常学杂志, 2020, 24(2):123-127. doi:10.3760/cma.j.cn.113859-20200304-00052.
[32]	Chen C, He W, Wang DW. Wuhan 3 years after the outbreak of the pandemic-cardiological insights and perspectives. Herz, 2023, 48(3):173-179. doi:10.1007/s00059-023-05176-4.
[33]	Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol, 2020, 5(7):802-810. doi:10.1001/jamacardio.2020.0950. pmid: 32211816
[34]	Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol, 2020, 5(7):811-818. doi:10.1001/jamacardio.2020.1017. pmid: 32219356
[35]	Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 2020, 323(11):1061-1069. doi:10.1001/jama.2020.1585. pmid: 32031570
[36]	Han H, Xie L, Liu R, et al. Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China. J Med Virol, 2020, 92(7):819-823. doi:10.1002/jmv.25809. pmid: 32232979
[37]	Muthyala A, Sasidharan S, John KJ. et al. Utility of cardiac bioenzymes in predicting cardiovascular outcomes in SARS-CoV-2. World J Virol, 2022, 11(5):375-390. doi:10.5501/wjv.v11.i5.375. pmid: 36188743